Pierce K.H. Chow, PhD, MBBS, on Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma: A Possible New Treatment Paradigm

Posted: Wednesday, April 19, 2023

Pierce K.H. Chow, PhD, MBBS, of the National Cancer Centre, Singapore and Duke-NUS Medical School, discusses his phase III findings from the IMbrave050 trial and the potential clinical significance of using atezolizumab plus bevacizumab vs active surveillance to treat patients with hepatocellular carcinoma at high risk of disease recurrence. (Abstract CT003)

---